Navigation Links
OptiNose Completes Series C-1 Financing
Date:8/4/2014

pon prior approaches to intranasal drug delivery. Available data, including two published Phase II trials, suggest that OPN-375 has the potential to be a breakthrough product that could be transformational in the treatment of serious chronic nasal inflammatory diseases like chronic rhinosinusitis with nasal polyps. A global late-phase clinical program for nasal polyps, comparable in scale to that required for a new molecular entity and enrolling over 1,500 patients, is underway. Enrollment is ongoing or completed in all planned trials. OptiNose is also working to ensure that other critical enablers of future OPN-375 product success, including a launch-ready supply chain and other appropriate pre-commercial efforts, are in place to bring the product to market immediately following regulatory review.

About OptiNose

OptiNose is a specialty pharmaceutical company built around a unique nasal delivery platform. The company is driven by an experienced, world-class team with expertise including drug and device development, product manufacturing and commercialization. OptiNose is focused on using its patented technology to identify and develop reduced-risk assets that create significant commercial value by offering meaningful new clinical benefits to patients and healthcare systems. The OptiNose closed-palate

Bi-Directional™ Breath Powered™ technology platform provides dramatically enhanced delivery of drug into the nasal cavity compared to current approaches. When used to deliver select medications for diseases where this type of delivery is important to targeting, efficacy or safety, this innovative technology platform can be a critical enabler for the development of valuable new products. OptiNose has an exciting pipeline of these assets for the treatment of diseases with significant unmet need. OptiNose was founded in 2000 and has corporate offices in Yardley, PA (USA), Oslo, Norway, a
'/>"/>

SOURCE OptiNose
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders
2. OptiNose mottar stipend for nese-til-hjerne-forskning innen spektrumet for autismesykdommer
3. MGC Diagnostics Corporation Completes Acquisition of MediSoft SA
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytrens Contracture In Japan
5. Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427
6. Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
7. TeraMedica Completes one of the Worlds Largest VNA Installations in New South Wales, Australia
8. Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data
9. Verus Healthcare Completes Over 85 Acquisitions
10. Virobay Completes $8 Million Series B Preferred Stock Financing
11. Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York , September 22, 2014 ... (MRI) market has been recently added to Transparency Market ... (MRI) Market: Global Market Analysis, Size, Share & Forecast ... MRI market, which valued US$ 3.9 billion in 2011, ... 2011 to 2017(the forecast period of the report), and ...
(Date:9/22/2014)... 2014  Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical ... today announced it has completed three phase 3 ... Obiltoxaximab is an anti-toxin in development for the ... studies support the safety and tolerability of the ... therapeutic dose. The conclusion of these studies marks ...
(Date:9/22/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... Ophthalmic Devices: Asia to Witness ... at USD 29,171.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... Market Study on Ophthalmic Devices:  Asia  to ...
Breaking Medicine Technology:Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 2Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 3Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Metformin, a ... risk of low levels of thyroid-stimulating hormone (TSH) among ... The researchers cautioned that low TSH levels may ... a cause-and-effect link was not established in this study. ... thyroid (hypothyroidism), there were 495 incidences of low levels ...
(Date:9/22/2014)... The “ Ztylus ” was featured on NewsWatch ... reviews and features the latest technology gadgets and services available ... expert, conducted the review and shared with viewers how it’s ... gives users four lens options for their camera. , The ... Tech Report, which reviews and features the latest technology gadgets ...
(Date:9/22/2014)... 2014 “The Race is On!” for the ... Sunday, October 12, 2014 as it moves to its new ... As the signature fundraising and awareness event for Susan G. ... Phoenix Race for the Cure provides supporters of all ages ... and even sleeping in. , “Moving the Race to ...
(Date:9/22/2014)... perspiration these symptoms are a few of the ... heart rate and plays a crucial role in its ... Aviv University points to an additional complication caused by ... Mammalian Genome , was conducted by Prof. Karen ... of Human Molecular Genetics and Biochemistry at TAU,s Sackler ...
(Date:9/22/2014)... A study led by University of North Carolina at ... the accurate diagnosis of people who are experiencing the ... delusions that define the development of severe mental disorders ... early adulthood and affects about 1 in every 100 ... person can be a life compromised, and the burden ...
Breaking Medicine News(10 mins):Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Lack of thyroid hormone blocks hearing development 2Health News:Blood test may help determine who is at risk for psychosis 2
... HOUSTON - A vaccine that turns the immune system ... drives the most aggressive form of glioblastoma multiforme improved ... researchers at Duke University and The University of Texas ... Journal of Clinical Oncology . Eighteen newly diagnosed ...
... Oct. 6, 2010 A set of proteins found in ... to diagnose Alzheimer,s disease, researchers at UT Southwestern Medical Center ... An analysis of the proteins, plus a clinical exam, proved ... accurate in ruling it out in people without the disease, ...
... Reinberg HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... young adults admit they are binge drinkers, health officials said ... as having four or more drinks for women, and five ... -- numbers that are different because men and women metabolize ...
... to a discovery by a Saint Louis University researcher, scientists ... better control cholesterol levels in blood. Led by ... at Saint Louis University and published in a recent issue ... of the United States of America, the study found that ...
... New neuroscience research by life scientists from UCLA and Australia may ... to brain injury or disease. By examining how ... way the brain first captures and encodes a situation or event ... The study is published in the Sept. 29 edition ...
... By Randy Dotinga HealthDay Reporter , ... study is the latest to suggest that testosterone may ... causing serious side effects. Researchers aren,t yet ready ... to female patients. However, the treatment does hold some ...
Cached Medicine News:Health News:Vaccine extends glioblastoma patients' survival in phase II trial 2Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 3Health News:Better cholesterol drugs may follow Saint Louis University researcher's breakthrough 2Health News:Neuroscience research may help patients recover from brain injury 2Health News:Testosterone Could Boost Health of Heart Failure Patients 2
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: